World Health Organization, Geneva, Switzerland.
Lancet Infect Dis. 2010 Mar;10(3):204-11. doi: 10.1016/S1473-3099(09)70329-9.
Gains in the control of malaria and the promising progress of a malaria vaccine that is partly efficacious do not reduce the need for a high-efficacy vaccine in the longer term. Evidence supports the feasibility of developing a highly efficacious malaria vaccine. However, design of candidate malaria vaccines remains empirical and is necessarily based on many unproven assumptions because much of the knowledge needed to design vaccines and to predict efficacy is not available. Data to inform key questions of vaccine science might allow the design of vaccines to progress to a less empirical stage, for example through availability of assay results associated with vaccine efficacy. We discuss six strategic gaps in knowledge that contribute to empiricism in the design of vaccines. Comparative evaluation, assay and model standardisation, greater sharing of information, collaboration and coordination between groups, and rigorous evaluation of existing datasets are steps that can be taken to enable reductions in empiricism over time.
疟疾控制方面的进展和部分有效的疟疾疫苗的前景,并没有降低长期内对高效疫苗的需求。有证据表明,开发高效疟疾疫苗是可行的。然而,候选疟疾疫苗的设计仍然是经验性的,并且必然基于许多未经证实的假设,因为设计疫苗和预测疗效所需的大部分知识尚不可用。提供信息以回答疫苗科学的关键问题的数据,可能会使疫苗的设计进入一个不那么经验性的阶段,例如,通过获得与疫苗疗效相关的检测结果。我们讨论了导致疫苗设计经验主义的 6 个知识战略差距。比较评估、检测和模型标准化、加强信息共享、小组之间的合作与协调,以及对现有数据集的严格评估,这些都是随着时间的推移减少经验主义的步骤。